Credit: Shutterstock photoAxonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to $16 range. Axonics previously filed to offer 6.7 million shares at the same range. Axonics Modulation Technologies plans to list on the Nasdaq under the symbol AXNX. BofA Merrill Lynch and Morgan Stanley acted as lead managers on the deal.
The article Shocking debut: Overactive bladder implant Axonics Modulation prices upsized $120 million IPO at $15 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
